Unlocking precision medicine for mesothelioma via integrating translational bioinformatics

Summary

Mesothelioma is an aggressive type of tumor with poor prognosis and modest overall survival rate. Notably, a significant proportion of the mesothelioma patients treated with the “one-size-fit-all” regimens comprised of immunotherapy and/or conventional chemotherapy do not respond or relapse following non-durable clinical responses. Indeed, this project will take advantage of the joint forces between multi-interdisciplinary team composed of scientists, pharmacologists, medicinal chemists as well as medical oncologists with world-class experience in basic and translational cancer research to systematically:

i) Identify reliable and sensitive prognostic biomarker(s) for patients with mesothelioma via exploiting bioinformatic analyses of the state-of-the-art multi-omics including genome-wide transcriptomics datasets of mesothelioma patients and validating their potential in biospecimens obtained from Egyptian mesothelioma patients,

ii) Investigate the potential role of the identified target(s) in mesothelioma pathogenesis  and

iii) Devise tolerable and effective therapies for mesothelioma via repurposing small molecules inhibiting this target as well as designing and synthesizing more potent and selective small molecules with potent anticancer activity against mesothelioma.

Importantly, this project will accelerate the implementation of precision medicine for mesothelioma patients.

Achievements

List of Publications from the Project

Partners

Project Members

• Roaa Yousry
• Eman Mahmoud Elawady Dokla

Project Leaders